NEWS 30 Jun, 2021 Industry Leaders Recommend Three Policies To Improve U.S. Response To Future Pandemics Read more here. Read More 16 Nov, 2020 SEKISUI Diagnostics Announces Launch of the OSOM® Ultra Plus Flu A&B Test in Europe High performance, point-of-care rapid test for the detection of Influenza A&B Burlington, MA – November 17, 2020 –SEKISUI Diagnostics announces it has received CE Marking (Conformité Européenne) for the [...] Read More 29 Jul, 2020 SEKISUI Diagnostics Invests £14.4 Million in cGMP Biopharma CDMO Capacity Burlington, MA, USA – July 29, 2020 – Sekisui announces the decision to invest £14.4 Million in its biopharma CDMO business aimed at cGMP microbial capacity expansion at the [...] Read More 9 Jun, 2020 Sekisui Diagnostics Discusses Pandemic Response With MA State Representative Ken Gordon Interviews with local companies in Massachusetts and how they have responded to the pandemic. Watch now! Read More 18 May, 2020 Sekisui Diagnostics Helping In Fight Against COVID-19 New to the Burlington, MA business community, Sekisui Diagnostics comes equipped to contribute to the ongoing effort against COVID-19. Watch now! Read More 29 Apr, 2020 2020 IFCC Distinguished Award for Laboratory Medicine and Patient Care Doctor David B. Sacks selected to receive the 2020 IFCC Distinguished Award for Laboratory Medicine and Patient Care Read Full Press Release Read More 4 Feb, 2020 SEKISUI CHEMICAL CO. LTD Named 2020 Global 100 Most Sustainable Corporations SEKISUI CHEMICAL CO. LTD. was once again recognized as one of the ‘Most Sustainable Corporations in the World’ in Corporate Knights, 2020 Global 100 Index ranking 12th (out of [...] Read More 23 Jan, 2020 New sore throat test and treat service available from local pharmacists thanks to new pilot scheme Read Full Article Read More 2 Dec, 2019 Sekisui Diagnostics PEI Named one of Canada’s Top 100 Employers of the Year Learn more! Read More 24 Nov, 2019 Sekisui Diagnostics Opens $1.9 Million Bioprocess Innovation Centre Burlington, MA, USA– 25th November 2019 – Sekisui Diagnostics’ Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK. The new R&D facility, costing [...] Read More 24 Oct, 2019 Sekisui Invests $1.9m in New Bioprocess Innovation Centre in the UK Click here for full story Read More 9 Jul, 2019 Sekisui Diagnostics Announces Relocation of Global Headquarters As of June 26, 2019, Sekisui Diagnostics global headquarters has relocated to One Wall Street, Burlington, MA. One Wall Street houses 14 companies and features a fitness center and [...] Read More 1 2 Next MEDIA CONTACT Lisa Turner Director, Marketing Communications Sekisui Diagnostics, LLC Office: 858-777-2660 lisa.turner@sekisui-dx.com RECENT NEWS Industry Leaders Recommend Three Policies To Improve U.S. Response To Future Pandemics SEKISUI Diagnostics Announces Launch of the OSOM Ultra Plus Flu A&B Test in Europe SEKISUI Diagnostics Invests £14.4 Million in cGMP Biopharma CDMO Capacity Sekisui Diagnostics Discusses Pandemic Response With MA State Representative Ken Gordon Sekisui Diagnostics Helping In Fight Against COVID-19 FROM OUR BLOG The Importance of Testing for Key Metabolite in Methadone The Coronavirus Pandemic Isn’t Over: Keep Washing Your Hands as Economies Reopen What Can We Expect This Coming Flu Season? ABOUT USPRODUCTSPRODUCT DOCUMENTATIONCAREERSCONTACT USDx DIALOGUE Copyright 2021 Sekisui Diagnostics | All Rights Reserved Privacy Policy | Terms of Use | Ordering Information | (UK) Modern Slavery and Human Trafficking By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Accept All Cookies